Licorice Root Extract Shows Antitumor Activity

Publication
Article
OncologyONCOLOGY Vol 14 No 2
Volume 14
Issue 2

A substance extracted from licorice root, Licochalcone-A, has been shown to have antitumor activity in acute leukemia, breast, and prostate cancer cell lines by lowering the amount of bcl-2, a drug-resistant protein. Excess amounts of this

A substance extracted from licorice root, Licochalcone-A, has been shown to have antitumor activity in acute leukemia, breast, and prostate cancer cell lines by lowering the amount of bcl-2, a drug-resistant protein. Excess amounts of this protein are frequently associated with these cancers. These findings were presented at the International Conference on Molecular Cancer Therapeutics sponsored by the American Association of Cancer Research (AACR), National Cancer Institute (NCI), and European Organization for Research and Treatment of Cancer (EORTC).

Protein May Cause Resistance to Anticancer Agents

“Bcl-2 is a protein that seems to cause resistance to anticancer agents. By decreasing the level of bcl-2, Licochalcone-A may increase tumor sensitivity to anticancer agents,” said Robert DiPaola, MD, assistant professor of medicine at the Robert Wood Johnson Medical School and the Cancer Institute of New Jersey, and senior investigator of this study. “Interestingly, neither of its parent compounds—chalcone and estradiol—has the same effect.”

Recent studies have demonstrated that certain estrogens may regulate the cancer gene bcl-2, which is produced in excess in some cancer cells and causes resistance to chemotherapy and most other traditional cancer treatments. It is sometimes referred to as a resistance protein. Licochalcone-A belongs to a class of compounds that sometimes have both estrogenic and antitumor activity. However, this is the first time that a compound from this class has been linked directly to bcl-2 and shows antitumor activity against hormone-responsive and hormone-unresponsive tumors.

Recent Videos
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Related Content